Literature DB >> 21292448

Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi.

Aline Araujo Zuma1, Danielle Pereira Cavalcanti, Marina C P Maia, Wanderley de Souza, Maria Cristina M Motta.   

Abstract

Trypanosomatids present unusual organelles, such as the kinetoplast that contains the mitochondrial DNA arranged in catenated circles. The nucleus of these protozoa presents distinct domains during interphase as well as a closed mitosis. DNA topoisomerases modulate the topological state of DNA by regulating supercoiling of the double-stranded DNA during replication, transcription, recombination and repair. Because topoisomerases play essential roles in cellular processes, they constitute a potential target for antitumour and antimicrobial drugs. In this study, the effects of various topoisomerase inhibitors and DNA-binding drugs were tested on the cellular proliferation and ultrastructure of the Trypanosoma cruzi epimastigote form Blastocrithidia culicis was used as a comparative model, which has a more relaxed kinetoplast DNA (kDNA) organization. The results showed that the eukaryotic topoisomerase I inhibitors camptothecin and rebeccamycin were the most effective compounds in the arrest of T. cruzi proliferation. Of the eukaryotic topoisomerase II inhibitors, mitoxantrone, but not merbarone, was effective against cell proliferation. The prokaryotic topoisomerase II inhibitors norfloxacin and enoxacin targeted the kinetoplast specifically, thus promoting ultrastructural kDNA rearrangement in B. culicis. Of the DNA-binding drugs, berenil caused remarkable kDNA disorganization. With the exception of camptothecin, there have been no previous evaluations of the compounds tested here on trypanosomatid ultrastructure. In conclusion, inhibitors of the same class may have different effects on trypanosomatid proliferation and ultrastructure. The results obtained in this work may help to reveal the mechanism of action of different topoisomerase inhibitors in trypanosomatids.
Copyright © 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21292448     DOI: 10.1016/j.ijantimicag.2010.11.031

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

1.  Online fast Biospeckle monitoring of drug action in Trypanosoma cruzi parasites by motion history image.

Authors:  Mohammad Zaheer Ansari; Hilda C Grassi; Humberto Cabrera; Ana Velásquez; Efrén D J Andrades
Journal:  Lasers Med Sci       Date:  2016-06-27       Impact factor: 3.161

2.  Unveiling the effects of berenil, a DNA-binding drug, on Trypanosoma cruzi: implications for kDNA ultrastructure and replication.

Authors:  Aline Araujo Zuma; Danielle Pereira Cavalcanti; Marcelo Zogovich; Ana Carolina Loyola Machado; Isabela Cecília Mendes; Marc Thiry; Antonio Galina; Wanderley de Souza; Carlos Renato Machado; Maria Cristina Machado Motta
Journal:  Parasitol Res       Date:  2014-10-29       Impact factor: 2.289

3.  Diminazene aceturate mitigates cardiomyopathy by interfering with renin-angiotensin system in a septic rat model.

Authors:  Zhaoqing Lu; Di Wu; Zheng Wang; Hanyu Zhang; Yufan Du; Guoxing Wang
Journal:  BMC Pharmacol Toxicol       Date:  2022-07-04       Impact factor: 2.605

4.  Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis.

Authors:  Rafael Balaña-Fouce; Christopher F Prada; José María Requena; Mark Cushman; Yves Pommier; Raquel Álvarez-Velilla; José Miguel Escudero-Martínez; Estefania Calvo-Álvarez; Yolanda Pérez-Pertejo; Rosa M Reguera
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

5.  A lupane-triterpene isolated from Combretum leprosum Mart. fruit extracts that interferes with the intracellular development of Leishmania (L.) amazonensis in vitro.

Authors:  Carolina Bioni Garcia Teles; Leandro Soares Moreira-Dill; Alexandre de Almeida Silva; Valdir Alves Facundo; Walter F de Azevedo; Luiz Hildebrando Pereira da Silva; Maria Cristina M Motta; Rodrigo Guerino Stábeli; Izaltina Silva-Jardim
Journal:  BMC Complement Altern Med       Date:  2015-06-06       Impact factor: 3.659

6.  Isobenzofuranone derivative JVPH3, an inhibitor of L. donovani topoisomerase II, disrupts mitochondrial architecture in trypanosomatid parasites.

Authors:  Somenath Roy Chowdhury; Joseane Lima Prado Godinho; Jayaraman Vinayagam; Aline Araujo Zuma; Sara Teixeira De Macedo Silva; Parasuraman Jaisankar; Juliany Cola Fernandes Rodrigues; Wanderley De Souza; Hemanta K Majumder
Journal:  Sci Rep       Date:  2018-08-09       Impact factor: 4.379

7.  Independence from Kinetoplast DNA maintenance and expression is associated with multidrug resistance in Trypanosoma brucei in vitro.

Authors:  Matthew K Gould; Achim Schnaufer
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 8.  The double-edged sword in pathogenic trypanosomatids: the pivotal role of mitochondria in oxidative stress and bioenergetics.

Authors:  Rubem Figueiredo Sadok Menna-Barreto; Solange Lisboa de Castro
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

9.  Effects of camptothecin derivatives and topoisomerase dual inhibitors on Trypanosoma cruzi growth and ultrastructure.

Authors:  Otto Kischlat Lacombe; Aline Araujo Zuma; Camila Cristina da Silva; Wanderley de Souza; Maria Cristina M Motta
Journal:  J Negat Results Biomed       Date:  2014-06-10

10.  High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi.

Authors:  Jean A Bernatchez; Emily Chen; Mitchell V Hull; Case W McNamara; James H McKerrow; Jair L Siqueira-Neto
Journal:  Microorganisms       Date:  2020-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.